Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)

Introduction: Docetaxel plus ramucirumab could be a promising treatment for chemo-naive elderly patients with NSCLC, but high incidence of febrile neutropenia (FN) is a critical concern. We thus adopted a routine primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) to red...

Full description

Bibliographic Details
Main Authors: Motoko Tachihara, MD, PhD, Akito Hata, MD, Takaaki Tokito, MD, PhD, Satoshi Hara, MD, PhD, Hideaki Okada, MD, Satoru Miura, MD, PhD, Yuki Sato, MD, Eriko Tabata, MD, PhD, Hiroshi Watanabe, MD, PhD, Yusuke Takayama, MD, PhD, Ryo Toyozawa, MD, PhD, Keiichi Ota, MD, PhD, Kazushige Wakuda, MD, PhD, Atsushi Nakamura, MD, PhD, Mototsugu Shimokawa, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:JTO Clinical and Research Reports
Subjects:
Docetaxel
Ramucirumab
Febrile neutropenia
pegylated-granulocyte-colony stimulating factor
elderly
Non–small cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001121

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001121

Similar Items